Literature DB >> 17387584

MDR1 hypermethylation contributes to the progression of neuroblastoma.

Y-Yong Qiu1, Bernard L Mirkin, Rama S Dwivedi.   

Abstract

MDR1 hypermethylation plays an important role in pathogenesis and progression of neuroblastoma tumors. This hypothesis was tested by studying the methylation status of MDR1 gene promoter in neureoblastoma biopsy specimens during the progression of tumor from stage-1 to stage-4. Results of our findings demonstrate an inverse correlation between the methylation status of MDR1 promoter and MDR1 expression during the progression of disease from stage-1 to stage-4 as determined by methylation specific PCR (MSP) and RT/PCR analyses. The results of the RT/PCR and MSP analyses were validated by quantitative Real Time PCR analysis. Data from present study suggest that transcriptional inactivation of MDR1 gene due to increased MDR1 promoter methylation may be a contributing factor in pathogenesis and progression of neuroblastoma tumors, and may be used in designing an effective treatment therapy to neuroblastoma patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17387584     DOI: 10.1007/s11010-006-9404-3

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.842


  20 in total

1.  Inverse relationship between P-glycoprotein expression and its proliferative activity in hepatocellular carcinoma.

Authors:  K Takanishi; M Miyazaki; M Ohtsuka; N Nakajima
Journal:  Oncology       Date:  1997 May-Jun       Impact factor: 2.935

Review 2.  P-glycoprotein: its role in drug resistance.

Authors:  V Ling
Journal:  Am J Med       Date:  1995-12-29       Impact factor: 4.965

3.  The International Neuroblastoma Pathology Classification (the Shimada system).

Authors:  H Shimada; I M Ambros; L P Dehner; J Hata; V V Joshi; B Roald; D O Stram; R B Gerbing; J N Lukens; K K Matthay; R P Castleberry
Journal:  Cancer       Date:  1999-07-15       Impact factor: 6.860

4.  Precipitous release of methyl-CpG binding protein 2 and histone deacetylase 1 from the methylated human multidrug resistance gene (MDR1) on activation.

Authors:  Assam El-Osta; Phillip Kantharidis; John R Zalcberg; Alan P Wolffe
Journal:  Mol Cell Biol       Date:  2002-03       Impact factor: 4.272

5.  Role of chemotherapy resistance genes in outcome of neuroblastoma.

Authors:  Patricia de Cremoux; Nathalie Jourdan-Da-Silva; Jérôme Couturier; Carine Tran-Perennou; Gudrun Schleiermacher; Pascale Fehlbaum; François Doz; Véronique Mosseri; Olivier Delattre; Jerzy Klijanienko; Philippe Vielh; Jean Michon
Journal:  Pediatr Blood Cancer       Date:  2007-03       Impact factor: 3.167

6.  Biology of neuroblastomas that were found by mass screening at 6 months of age in Japan.

Authors:  Yasuhiko Kaneko; Hirofumi Kobayashi; Naoki Watanabe; Nobumoto Tomioka; Akira Nakagawara
Journal:  Pediatr Blood Cancer       Date:  2006-03       Impact factor: 3.167

7.  The expression of drug resistance gene products during the progression of human prostate cancer.

Authors:  G F Sullivan; P S Amenta; J D Villanueva; C J Alvarez; J M Yang; W N Hait
Journal:  Clin Cancer Res       Date:  1998-06       Impact factor: 12.531

8.  Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands.

Authors:  J G Herman; J R Graff; S Myöhänen; B D Nelkin; S B Baylin
Journal:  Proc Natl Acad Sci U S A       Date:  1996-09-03       Impact factor: 11.205

9.  Profiling methyl-CpG specific determinants on transcriptionally silent chromatin.

Authors:  A El-Osta; E K Baker; A P Wolffe
Journal:  Mol Biol Rep       Date:  2001       Impact factor: 2.316

10.  Tumor suppressor gene hypermethylation as a predictor of gastric stromal tumor behavior.

Authors:  Michael G House; MingZhou Guo; David T Efron; Keith D Lillemoe; John L Cameron; James E Syphard; Craig M Hooker; Susan C Abraham; Elizabeth A Montgomery; James G Herman; Malcolm V Brock
Journal:  J Gastrointest Surg       Date:  2003-12       Impact factor: 3.267

View more
  5 in total

1.  Knowing your ABCCs: novel functions of ABCC transporters.

Authors:  Garrett M Brodeur
Journal:  J Natl Cancer Inst       Date:  2011-07-28       Impact factor: 13.506

Review 2.  Beyond genetics: epigenetic code in chronic kidney disease.

Authors:  Rama S Dwivedi; James G Herman; Timothy A McCaffrey; Dominic S C Raj
Journal:  Kidney Int       Date:  2010-09-29       Impact factor: 10.612

3.  Potency of non-steroidal anti-inflammatory drugs in chemotherapy.

Authors:  Lucia Hiľovská; Rastislav Jendželovský; Peter Fedoročko
Journal:  Mol Clin Oncol       Date:  2014-10-16

4.  Membrane expression of MRP-1, but not MRP-1 splicing or Pgp expression, predicts survival in patients with ESFT.

Authors:  E Roundhill; S Burchill
Journal:  Br J Cancer       Date:  2013-06-25       Impact factor: 7.640

Review 5.  Methylation of DNA and chromatin as a mechanism of oncogenesis and therapeutic target in neuroblastoma.

Authors:  Ram Mohan Ram Kumar; Nina Felice Schor
Journal:  Oncotarget       Date:  2018-04-24
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.